In our previous studies, we assessed the early diagnostic value of autoantibodies against a panel of six TAAs (BMI-1, HSP70, MMP-7, NY-ESO-1, p53 and PRDX6) in esophagogastric junction adenocarcinoma and esophageal squamous cell carcinoma, and the results were validated in independent cohorts 16, 17. Here, TP53 is linked to gastroesophageal junction adenocarcinoma.